|

Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy

RECRUITINGSponsored by Aesculap AG
Actively Recruiting
SponsorAesculap AG
Started2024-03-19
Est. completion2026-07
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted

Summary

The aim of this study is to show the superiority of the new unidirectional barbed suture (SYMMCORA® mid-term, unidirectional) to conventional suture material in terms of time to perform the vaginal cuff closure during gynecologic surgeries without an increase in the complication rate. Secondly, the superiority of SYMMCORA®, mid-term unidirectional compared to the V-Loc®, unidirectional will be assessed regarding the mean time to close the vaginal cuff. The study will be performed in routine clinical setting, the only difference will be the randomization into two different suture groups. Both suture materials which will be applied to approximate the vaginal cuff are approved and carrying the CE-marks. Additionally, both sutures will be applied in their intended use. Neither additional invasive measures nor additional burden in regard to the patient will be performed.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Females undergoing an elective, laparoscopic total hysterectomy
* Age ≥ 18 years
* Written informed consent

Exclusion Criteria:

* Emergency surgery
* Open surgery
* Patients undergone immunosuppressive drug treatment within the prior 6 months
* Patients with hypersensitivity or allergy to the suture material.
* Participation in another clinical study
* Non-compliance of patient

Conditions9

Abnormal Uterine BleedingCancerCervical CancerEndometrial CancerEndometriosisFallopian Tube CancerOvarian CancerUterine CancerUterine Prolapse

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.